Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Daiichi Sankyo
Harvard Business School
Moodys
Boehringer Ingelheim
Express Scripts
Queensland Health
Cerilliant

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022406

« Back to Dashboard

NDA 022406 describes XARELTO, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the XARELTO profile page.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rivaroxaban profile page.
Summary for 022406
Tradename:XARELTO
Applicant:Janssen Pharms
Ingredient:rivaroxaban
Patents:5
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022406
Generic Entry Date for 022406*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022406
Mechanism of ActionFactor Xa Inhibitors
Medical Subject Heading (MeSH) Categories for 022406
Suppliers and Packaging for NDA: 022406
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XARELTO rivaroxaban TABLET;ORAL 022406 NDA Janssen Pharmaceuticals, Inc. 50458-580 50458-580-07 7 TABLET, FILM COATED in 1 BOTTLE (50458-580-07)
XARELTO rivaroxaban TABLET;ORAL 022406 NDA Janssen Pharmaceuticals, Inc. 50458-580 50458-580-10 10 BLISTER PACK in 1 CARTON (50458-580-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Jul 1, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 27, 2020
Regulatory Exclusivity Use:NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
Patent:➤ Sign UpPatent Expiration:Aug 28, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Patent:➤ Sign UpPatent Expiration:Aug 28, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PULMONARY EMBOLISM (PE)

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Cipla
QuintilesIMS
Boehringer Ingelheim
McKesson
Daiichi Sankyo
US Army
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.